Mantle Cell Lymphoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight

DelveInsight's "Mantle Cell Lymphoma Treatment Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Mantle cell lymphoma, historical and forecasted epidemiology as well as the Mantle Cell Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

Discover which therapies are expected to grab the Mantle Cell Lymphoma Market Share @ Mantle Cell Lymphoma Market Outlook- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Mantle Cell Lymphoma Market Report
• In May 2025, Loxo Oncology Inc. announced a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
• In May 2025, Acerta Pharma BV conducted a Phase 2 study in subjects with histologically documented MCL, who have relapsed after, or were refractory to, ≥ 1 (but not > 5) prior treatment regimens. Subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (BID) in repeated 28-day cycles.
• In May 2025, BeiGene organized a study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo
• As per Lynch et al., (2022), Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200,000 people. MCL comprises around 5% of all.
• The leading Mantle Cell Lymphoma Companies such as Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical and others.
• Promising Mantle Cell Lymphoma Pipeline Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Pirtobrutinib, Ibrutinib., Acalabrutinib, Rituximab, Zanubrutinib and others.

Stay ahead in the Mantle Cell Lymphoma Treatment Market with DelveInsight's Strategic Report @ Mantle Cell Lymphoma Market Outlook- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mantle Cell Lymphoma Epidemiology Segmentation in the 7MM
• Total Mantle Cell Lymphoma Incident Cases
• Total Mantle Cell Lymphoma Diagnosed Cases
• Total Mantle Cell Lymphoma Gender-specific Cases
• Total Mantle Cell Lymphoma Age-specific Cases
• Total Mantle Cell Lymphoma Stage-specific Cases
• Total Mantle Cell Lymphoma Treated Cases

Download the report to understand which factors are driving Mantle Cell Lymphoma Epidemiology trends @ Mantle Cell Lymphoma Prevalence- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mantle Cell Lymphoma Marketed Drugs
• BRUKINSA (zanubrutinib): BeiGene
BRUKINSA (zanubrutinib) is a small-molecule inhibitor of BTK. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.

• IMBRUVICA (ibrutinib): Janssen Biotech
IMBRUVICA (ibrutinib) is an orally available, selective inhibitor of Bruton's tyrosine kinase (Btk). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. In November 2013, the Food and Drug Administration granted approval to ibrutinib for the treatment of patients with Mantle Cell Lymphoma who have received at least one prior therapy.

Mantle Cell Lymphoma Emerging Drugs
• Pirtobrutinib is an investigational, oral, highly-selective non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. It is currently being studied in multiple Mantle cell lymphoma clinical trials. Currently, the drug is in Phase III comparing pirtobrutinib to investigator's choice of ibrutinib, acalabrutinib or zanubrutinib in MCL patients who have received 1 or more lines of therapy and are BTK inhibitor naïve which is anticipated to be complete by April 2025.

• NVG-111 is a first-in-class bispecific antibody T-cell engager for haematological and solid malignancies that targets the Receptor Tyrosine Kinase like Orphan like Receptor 1 (ROR1). The NVG-111 initiative will first concentrate on Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. It is designed to be extremely efficient in killing cancer cells while sparing healthy B cells. NVG-111 can target cancer initiating stem cells (CSCs), a subpopulation of cancer cells that are resistant to standard cancer therapies and is believed to be the only T cell engager in development that can kill CSCs, potentially reducing the risk of tumor recurrence. Currently, the drug is in Phase I/II clinical trial which is anticipated to be complete by December 2023.

To learn more about Mantle Cell Lymphoma treatment guidelines, visit @ Mantle Cell Lymphoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mantle Cell Lymphoma Companies
Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical and others.

Mantle Cell Lymphoma Market Outlook
The current treatment strategies for Mantle Cell Lymphoma primarily depends on multiple factors, including stage of disease, age of the patient, and patient's overall health. Mantle Cell Lymphoma is usually diagnosed once it has spread throughout the body, and the majority of these patients require treatment. While Mantle Cell Lymphoma is considered as difficult cancer to treat, tremendous progress has been made in discovery of new treatments for the disease. In general, the current recommended mainstays for this specific cancer ailment includes Active Surveillance, Chemotherapy, Targeted therapy, and Transplantation.

Mantle Cell Lymphoma Therapeutics Market
The leading Mantle Cell Lymphoma Companies such as Bristol-Myers Squibb (BMS), Takeda, Acerta Pharma/ AstraZeneca, and many others. Expected launch of emerging therapies such as, NVG-111 (Novalgen), HMPL-760 (Hutchison medipharma, Pirtobrutinib, Orelabrutinib (Beijing InnoCare Pharma Tech), LOXO-338 (Eli Lilly and Company), and others will significantly impact the Mantle Cell Lymphoma market during the forecast period (2023-2032).

Learn more about the FDA-approved drugs for Mantle Cell Lymphoma @ Drugs for Mantle Cell Lymphoma Treatment- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Mantle Cell Lymphoma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Mantle Cell Lymphoma Companies- Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical and others.
• Mantle Cell Lymphoma Pipeline Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Pirtobrutinib, Ibrutinib., Acalabrutinib, Rituximab, Zanubrutinib and others.
• Mantle Cell Lymphoma Market Dynamics: Mantle Cell Lymphoma Market Drivers and Barriers
• Mantle Cell Lymphoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Mantle Cell Lymphoma Drugs in development @ Mantle Cell Lymphoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Mantle Cell Lymphoma Market Report Introduction
3. Mantle Cell Lymphoma Market Overview at a Glance
4. Mantle Cell Lymphoma Executive Summary
5. Disease Background and Overview: Mantle Cell Lymphoma
6. Mantle Cell Lymphoma Epidemiology and Patient Population
7. Patient Journey
8. Key Endpoints for Mantle Cell Lymphoma Clinical Trials
9. Mantle Cell Lymphoma Marketed Therapies
10. Mantle Cell Lymphoma Emerging Therapies
11. Conjoint Analysis
12. Mantle Cell Lymphoma: 7 Major Market Analysis
13. Mantle Cell Lymphoma Market Access and Reimbursement
14. Mantle Cell Lymphoma SWOT Analysis
15. Mantle Cell Lymphoma Unmet Needs
16. Mantle Cell Lymphoma KOL views
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.